NASDAQ:OCUL - Ocular Therapeutix Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.7750 +0.04 (+0.52 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$7.7750
Today's Range$7.45 - $7.79
52-Week Range$3.30 - $11.00
Volume868,966 shs
Average Volume417,430 shs
Market Capitalization$288.17 million
P/E Ratio-3.53
Dividend YieldN/A
Ocular Therapeutix logoOcular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.22
Current Ratio4.90
Quick Ratio4.89


Trailing P/E Ratio-3.53
Forward P/E Ratio-4.18
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.92 million
Price / Sales150.96
Cash FlowN/A
Price / CashN/A
Book Value$0.72 per share
Price / Book10.80


EPS (Most Recent Fiscal Year)($2.20)
Net Income$-63,380,000.00
Net Margins-3,418.79%
Return on Equity-153.53%
Return on Assets-88.54%


Outstanding Shares37,280,000

The Truth About Cryptocurrencies

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix Inc (NASDAQ:OCUL) posted its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.02. The biopharmaceutical company earned $0.34 million during the quarter. Ocular Therapeutix had a negative net margin of 3,418.79% and a negative return on equity of 153.53%. View Ocular Therapeutix's Earnings History.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Ocular Therapeutix.

What price target have analysts set for OCUL?

5 analysts have issued 1 year target prices for Ocular Therapeutix's shares. Their predictions range from $8.00 to $22.00. On average, they anticipate Ocular Therapeutix's stock price to reach $13.00 in the next twelve months. View Analyst Ratings for Ocular Therapeutix.

What are Wall Street analysts saying about Ocular Therapeutix stock?

Here are some recent quotes from research analysts about Ocular Therapeutix stock:
  • 1. HC Wainwright analysts commented, "We continue to believe that Dextenza has the potential to obtain regulatory approval in the U.S. by the end of 2018 and start generating revenue around mid-2019. The company plans to apply for a pass-through reimbursement status (C code) for Dextenza. With bundled pricing of cataract surgery, Dextenza should be priced above $480 per dose according to CMS guidelines, in our view. In the wake of this update, we reiterate our Buy rating and $10 price target." (6/21/2018)
  • 2. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/25/2018)
  • 3. BTIG Research analysts commented, "On Thursday, before market open, the management team of Ocular Therapeutix hosted their 4Q17 earnings call. We think the updates provided on the call were in line with expectations. The company expects to resubmit the Dextenza NDA during 1H2018, with an FDA decision likely by YE2018. Key leadership positions have also been filled including the hiring of experienced quality and regulatory personnel, which we think could further provide additional investor confidence moving forward. We reiterate our Buy rating and $9 Price Target." (3/11/2018)
  • 4. Cantor Fitzgerald analysts commented, "Potential Approval before The End of The Year. After receiving feedback earlier this year, Ocular believes the complete and clear nature of the FDA’s responses removes the need for a meeting to obtain additional feedback. Currently, the company is conducting on-going manufacturing runs in order to establish and support confidence limits for particulate observed. Based on the focus on manufacturing, we anticipate a Type 2 review, consistent with a manufacturing inspection and six month review timeline." (3/8/2018)

Who are some of Ocular Therapeutix's key competitors?

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the folowing people:
  • Dr. Amarpreet Sawhney, Founder & Exec. Chairman (Age 51)
  • Mr. Antony Mattessich, Pres, CEO & Director (Age 51)
  • Mr. Donald Notman Jr., Chief Financial Officer
  • Dr. Michael H. Goldstein, Chief Medical Officer (Age 51)
  • Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 56)

Has Ocular Therapeutix been receiving favorable news coverage?

Press coverage about OCUL stock has trended somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ocular Therapeutix earned a coverage optimism score of 0.07 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Summer Road LLC (8.12%), BlackRock Inc. (4.55%), Deltec Asset Management LLC (1.57%), Northern Trust Corp (0.87%), Schwab Charles Investment Management Inc. (0.14%) and California State Teachers Retirement System (0.12%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Institutional Ownership Trends for Ocular Therapeutix.

Which major investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Ocular Therapeutix.

Which major investors are buying Ocular Therapeutix stock?

OCUL stock was purchased by a variety of institutional investors in the last quarter, including Summer Road LLC, Deltec Asset Management LLC, BlackRock Inc., Northern Trust Corp, Barclays PLC, Millennium Management LLC, The Manufacturers Life Insurance Company and GSA Capital Partners LLP. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag and Donald Notman. View Insider Buying and Selling for Ocular Therapeutix.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $7.7750.

How big of a company is Ocular Therapeutix?

Ocular Therapeutix has a market capitalization of $288.17 million and generates $1.92 million in revenue each year. The biopharmaceutical company earns $-63,380,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Ocular Therapeutix employs 119 workers across the globe.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]

MarketBeat Community Rating for Ocular Therapeutix (OCUL)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  121 (Vote Underperform)
Total Votes:  344
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.